tbuckley/cabot-search huggingface dataset:
Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ
Authors: Ann C. Raldow, David Sher, Aileen B. Chen, Abram Recht, Rinaa S. Punglia
Journal: Journal of Clinical Oncology (2016)

Purpose The Oncotype DX DCIS Score short form (DCIS Score) estimates the risk of an ipsilateral breast event (IBE) in patients with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery without adjuvant radiation therapy (RT). We determined the cost effectiveness of strategies using this test. Materials and Methods We developed a Markov model simulating 10-year outcomes for 60-year-old women eligible for the Eastern Cooperative Oncology Group E5194 study (cohort 1: low/intermediate-grade DCIS, ≤ 2.5 cm; cohort 2: high-grade DCIS, ≤ 1 cm) with each of five strategies: (1) no testing, no RT; (2) no testing, RT only for cohort 2; (3) no RT for low-grade DCIS, test for intermediate- and high-grade DCIS, RT for intermediate- or high-risk scores; (4) test all, RT for intermediate- or high-risk scores; and (5) no testing, RT for all. We used utilities and costs extracted from the literature and Medicare claims to determine incremental cost-effectiveness ratios and examined the number of women needed to irradiate per IBE prevented. Results No strategy using the DCIS Score was cost effective. The most cost-effective strategy (RT for none or RT for all) was sensitive to small differences between the utilities of receiving or not receiving RT and remaining without recurrence. The numbers needed to irradiate per IBE prevented were 10.5, 9.1, 7.5, and 13.1 for strategies 2 to 5, respectively, relative to strategy 1. Conclusion Strategies using the DCIS Score lowered the proportion of women undergoing RT per IBE prevented. However, no strategy incorporating the DCIS Score was cost effective. The cost effectiveness of RT was exquisitely utility sensitive, highlighting the importance of engaging patient preferences in this decision. Physicians should discuss trade-offs associated with omitting or adding adjuvant RT with each patient to maximize quality-of-life outcomes.
Non Hodgkin's Lymphomas in 137 patients aged 70 years or older: a retrospective EORTC Lymphoma Group Study
Authors: U. Tirelli, V. Zagonel, D. Serraino, José Thomas, B. Hoerni, A. Tanguy, U. Ruhl, P. Bey, M. Tubiana, W.P.M. Breed, K.J. Roozendaal, A. Hagenbeek, P.S. Hupperets, R. Somers
Journal: Journal of Clinical Oncology (1988)
P2-276: Efficacy of adjuvant or neoadjuvant chemotherapy with surgical resection of stage lB-llB Non-small-cell lung cancer
Authors: Jeong Eun Lee, Mi-Kyong Joung, Yu-Jin Lee, Hee-Sun Park, Sung-Soo Jung, Ju-Ock Kim, Sun-Young Kim
Journal: Journal of Thoracic Oncology (2007)
Comment on: “Risk of subsequent melanoma after melanoma in situ and invasive melanoma: A population-based study from 1973 to 2011”
Authors: Claire S. Leitch, Catriona G. Sinclair, Silvia Aguilar-Duran, Anusha P. Panthagani, Ruth Ray, Gina M. Kavanagh
Journal: Journal of the American Academy of Dermatology (2016)
P2-297: Phase II trial of weekly docetaxel and gemcitabine for chemotherapy-naive patients with advanced non-small cell lung cancer
Authors: Joon Sik Hong, Yujin Kim, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Se Hoon Park, Eun Kyung Cho, Dong Bok Shin
Journal: Journal of Thoracic Oncology (2007)
Atherosclerosis-Driven Treg Plasticity Results in Formation of a Dysfunctional Subset of Plastic IFNγ <sup>+</sup> Th1/Tregs
Authors: Matthew J. Butcher, Adam R. Filipowicz, Tayab C. Waseem, Christopher M. McGary, Kevin J. Crow, Nathaniel Magilnick, Mark Boldin, Patric S. Lundberg, Elena V. Galkina
Journal: Circulation Research (2016)

Forkhead box P3+ T regulatory cells (Tregs) are key players in maintaining immune homeostasis. Evidence suggests that Tregs respond to environmental cues to permit or suppress inflammation. In atherosclerosis, Th1-driven inflammation affects Treg homeostasis, but the mechanisms governing this phenomenon are unclear.Here, we address whether atherosclerosis impacts Treg plasticity and functionality in Apoe-/- mice, and what effect Treg plasticity might have on the pathology of atherosclerosis.We demonstrate that atherosclerosis promotes Treg plasticity, resulting in the reduction of CXCR3+ Tregs and the accumulation of an intermediate Th1-like interferon (IFN)-γ+CCR5+ Treg subset (Th1/Tregs) within the aorta. Importantly, Th1/Tregs arise in atherosclerosis from bona fide Tregs, rather than from T-effector cells. We show that Th1/Tregs recovered from atherosclerotic mice are dysfunctional in suppression assays. Using an adoptive transfer system and plasticity-prone Mir146a-/- Tregs, we demonstrate that elevated IFNγ+ Mir146a-/- Th1/Tregs are unable to adequately reduce atherosclerosis, arterial Th1, or macrophage content within Apoe-/- mice, in comparison to Mir146a+/+ Tregs. Finally, via single-cell RNA-sequencing and real-time -polymerase chain reaction, we show that Th1/Tregs possess a unique transcriptional phenotype characterized by coexpression of Treg and Th1 lineage genes and a downregulation of Treg-related genes, including Ikzf2, Ikzf4, Tigit, Lilrb4, and Il10. In addition, an ingenuity pathway analysis further implicates IFNγ, IFNα, interleukin-2, interleukin-7, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), T-cell receptor, and Csnk2b-related pathways in regulating Treg plasticity.Atherosclerosis drives Treg plasticity, resulting in the accumulation of dysfunctional IFNγ+ Th1/Tregs that may permit further arterial inflammation and atherogenesis.
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Authors: Arabella Young, Shin Foong Ngiow, Deborah S. Barkauskas, Erin Sult, Carl Hay, Stephen J. Blake, Qihui Huang, Jing Liu, Kazuyoshi Takeda, Michele W.L. Teng, Kris Sachsenmeier, Mark J. Smyth
Journal: Cancer Cell (2016)
Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma
Authors: Wenjing Zhang, Yu Zhang, Yong Zhang, Yuji Mishima, Michaela Reagan, Siobhan Glavey, Antonio Sacco, Aldo M Roccaro, Irene M Ghobrial
Journal: Blood (2013)
Low-dose nab-paclitaxel-based combination chemotherapy in heavily-pretreated pancreatic or ampullary cancer patients: Taiwanese single-center case series.
Authors: Shih-Hung Yang, Jhe-Cyuan Guo, Chiun Hsu, Chih-Hung Hsu, Sung Hsin Kuo, Ann-Lii Cheng, Kun-Huei Yeh
Journal: Journal of Clinical Oncology (2016)

e15695 Background: In heavily-pretreated periampullary cancer patients, the prognosis remains poor, and no standard salvage therapy exists. Methods: Pancreatic or ampullary cancer patients who had been treated with nab-paclitaxel (Nab-P) for palliation after failure of gemcitabine and/or fluoropyrimidines were retrospectively reviewed at National Taiwan University Hospital among Year 2013-2015. Results: Thirty-nine patients were identified (M/F: 27/12; median age of years: 64, range 24-86; pancreas/ampulla: 36/3). Initial stage was I, II, III, IV in 1, 20, 3, and 15 patients, respectively. Twenty-one patients had received curative surgery. Median recurrence-free survival was 3.2 (95% CI: 2.7-3.7) months. Adjuvant therapy had been given in 16 patients. Median prior lines of treatment were 2 (range 1-6). Nineteen (49%) patients had ECOG performance status ≥ 2. Best response to prior therapy was complete or partial response (PR) in 6 patients and stable disease (SD) in 8 patients. Namely, the Nab-P-based regimens included Nab-P/gemcitabine (Nab-PG, N = 27), Nab-P/platinum/5-FU analogs (Nab-PPF, N = 7), Nab-P/5-FU analogs (N = 3), Nab-P/gemcitabine/S-1 (N = 1), and Nab-P/irinotecan/5-FU (Nab-PIF, N = 1). The median dose of nab-paclitaxel was 65 (range 51-128) mg/m2/dose with the schedule of D1/15, D1/8, and D1/8/15 in 22, 14, and 3 patients, respectively. One PR and four SD were observed with Nab-PG, one SD with Nab-PPF, and one SD with Nab-PIF. Progressive disease was observed in 22 patients; 10 patients were not evaluable. Median progression-free survival was 2.6 (95% CI: 2.1-3.0) months. Median overall survival was 5.1 (95% CI: 4.4-5.9) months. Hematological toxicities were significant with ≥ Gr3 leucopenia and/or neutropenia in 4 patients, and anemia in 5 patients. Granulocyte-colony stimulating factor was used in 21 patients for prophylaxis or rescue. Significant ( ≥ Gr3) non-hematological toxicities except infection (N = 7) were not frequent. Conclusions: In heavily-pretreated periampullary cancer patients, combination chemotherapy with relatively low doses of Nab-P is fairly tolerable with modest efficacy.
Induction of Therapeutic Hypothermia During Out-of-Hospital Cardiac Arrest Using a Rapid Infusion of Cold Saline
Authors: Stephen A. Bernard, Karen Smith, Judith Finn, Cindy Hein, Hugh Grantham, Janet E. Bray, Conor Deasy, Michael Stephenson, Teresa A. Williams, Lahn D. Straney, Deon Brink, Richard Larsen, Chris Cotton, Peter Cameron
Journal: Circulation (2016)

Background: Patients successfully resuscitated by paramedics from out-of-hospital cardiac arrest often have severe neurologic injury. Laboratory and observational clinical reports have suggested that induction of therapeutic hypothermia during cardiopulmonary resuscitation (CPR) may improve neurologic outcomes. One technique for induction of mild therapeutic hypothermia during CPR is a rapid infusion of large-volume cold crystalloid fluid. Methods: In this multicenter, randomized, controlled trial we assigned adults with out-of-hospital cardiac arrest undergoing CPR to either a rapid intravenous infusion of up to 2 L of cold saline or standard care. The primary outcome measure was survival at hospital discharge; secondary end points included return of a spontaneous circulation. The trial was closed early (at 48% recruitment target) due to changes in temperature management at major receiving hospitals. Results: A total of 1198 patients were assigned to either therapeutic hypothermia during CPR (618 patients) or standard prehospital care (580 patients). Patients allocated to therapeutic hypothermia received a mean (SD) of 1193 (647) mL cold saline. For patients with an initial shockable cardiac rhythm, there was a decrease in the rate of return of a spontaneous circulation in patients who received cold saline compared with standard care (41.2% compared with 50.6%, P =0.03). Overall 10.2% of patients allocated to therapeutic hypothermia during CPR were alive at hospital discharge compared with 11.4% who received standard care ( P =0.71). Conclusions: In adults with out-of-hospital cardiac arrest, induction of mild therapeutic hypothermia using a rapid infusion of large-volume, intravenous cold saline during CPR may decrease the rate of return of a spontaneous circulation in patients with an initial shockable rhythm and produced no trend toward improved outcomes at hospital discharge. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01173393.
P3-114: Erlotinib as first–line treatment for untreated patients with advanced or metastatic non–small cell lung cancer (NSCLC)
Authors: Carles Mesía, Adelaida García-Velasco, Enriqueta Felip, Carlos García-Girón, Daniel Almenar, Antonio Rueda, Angel Artal, Montserrat Gay, Pilar Regueiro, Bartomeu Massutí
Journal: Journal of Thoracic Oncology (2007)
O087 : IgG4+ B-cell receptor clones in peripheral blood distinguish IgG4-associated cholangitis/autoimmune pancreatitis from primary sclerosing cholangitis
Authors: L.M. Hubers, M.E. Doorenspleet, E.L. Culver, L.J. Maillette de Buy Wenniger, P.L. Klarenbeek, S.F. Van de Graaf, J. Verheij, T.M. Van Gulik, F. Baas, E. Barnes, N. De Vries, U. Beuers
Journal: Journal of Hepatology (2015)
Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3
Authors: Hye-Young Seo, Jae-Han Jeon, Yun-A Jung, Gwon-Soo Jung, Eun Ju Lee, Young-Keun Choi, Keun-Gyu Park, Mi Sun Choe, Byoung Kuk Jang, Mi-Kyung Kim, In-Kyu Lee
Journal: Kidney International (2016)
Oncology physicians' knowledge, attitudes, and practices regarding fertility preservation.
Authors: S. B. Goldfarb, M. N. Dickler, M. S. McCabe, B. Thom, X. Jia, C. Hudis, E. M. Basch, J. Kelvin
Journal: Journal of Clinical Oncology (2010)

e19525 Background: More than 2.5 million individuals of child-bearing age are currently survivors of cancer. Many of these patients wish to become parents after treatment, and are concerned about potential infertility from their therapy. It is unclear if oncologists feel qualified to discuss fertility issues with their patients, and if not, what barriers prevent such discussions. Methods: A survey was developed at Memorial Sloan- Kettering Cancer Center (MSKCC) for physicians to self-evaluate their knowledge, attitudes, and behaviors regarding fertility preservation. Survey items were derived from existing surveys in the literature and input from a multidisciplinary committee. The web-based survey was systematically administered to all MSKCC ambulatory physicians. Repeated email reminders were sent to optimize responses. Results: The survey was distributed between February 9 and February 25, 2009 and 149/395 (38%) physicians responded. Among respondents, there was widespread agreement 130/141 (92%) that patients should be informed of fertility preservation options and 100/144 (69%) reported access to information about infertility risks from treatment. However, significantly fewer respondents consistently discussed risks with their male 44/139 (32%) or female 68/140 (49%) patients. Many physicians cited lack of training in fertility preservation, time pressures, and lack of referral information as barriers to educating patients. No significant difference existed in practice or knowledge between physicians who were practicing for ≤ 5 years vs ≥ 5 years. Conclusions: Despite a widespread appreciation of the effects of cancer therapies on future fertility, physicians report that a lack of education, resources and insufficient time hinder fertility preservation discussions with patients. Physicians must be educated on fertility procedures and referral information to effectively educate patients. Physician time limitations may be overcome by developing educational resources and utilizing other clinical staff (e.g., nurses) to provide this information to patients. These findings are informing an institution-wide educational program on fertility preservation. No significant financial relationships to disclose.
Minimal Residual Disease as a Potential Surrogate End Point—Lingering Questions
Authors: Nicole J. Gormley, Ann T. Farrell, Richard Pazdur
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients
Authors: Jerzy Holowiecki, Sebastian Grosicki, Slawomira Kyrcz-Krzemien, Kazimierz Kuliczkowski, Aleksander B. Skotnicki, Andrzej Hellmann, Tadeusz Robak, Kazimierz Sulek, Anna Dmoszynska, Janusz Kloczko, Wieslaw Wiktor Jedrzejczak, Barbara Zdziarska, Krzysztof Warzocha, Krystyna Zawilska, Marek Kielbinski, Beata Piatkowska-Jakubas, Agnieszka Wierzbowska, Olga Haus, Beata Stella-Holowiecka, Malgorzata Krawczyk-Kulis, Malgorzata Wach, Anna Ejduk
Journal: Blood (2008)
P2-165: A phase I/II study of concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer
Authors: Anthony M. Brade, Andrea Bezjak, Robert MacRae, Scott Laurie, Andrea Afinec, Greg Pond, Neill Iscoe, Frances A. Shepherd
Journal: Journal of Thoracic Oncology (2007)
Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)
Authors: Florian Kuchenbauer, Donald W. Bunjes, Wolfgang Herr, Michael Heuser, Daniela Späth, Jochen Casper, Heinz-August Horst, Peter Brossart, Gerhard Held, Guido Kobbe, Mark Ringhoffer, Mohammed Wattad, Helmut R Salih, Katharina Götze, Gerald Wulf, Matthias Theobald, Mathias J Rummel, Walter Fiedler, Jörg Westermann, Hans Salwender, Andreas L. Petzer, Frank Hartmann, Michael Lübbert, Uwe Martens, Richard Greil, Hartmut H. Kirchner, Peter Paschka, Verena I. Gaidzik, Veronica Teleanu, Felicitas Thol, Gudrun Göhring, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk
Journal: Blood (2014)
Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor
Authors: Eng M. Tan, Josef S. Smolen
Journal: The Journal of Experimental Medicine (2016)

When studies on rheumatoid arthritis (RA) that were made many decades ago and could be considered “historical” in nature are analyzed in the context of recent observations, important insights on RA and on the function of rheumatoid factor (RF) become apparent. RF in the role of antibody to immune complexes (ICs) appears to be involved in activation of the complement system and in the production of chemotactic and inflammatory mediators, creating a condition that can be sustained and reinitiated. In the synovial cavity, a state of nonresolving inflammation is produced with the formation of citrullinated protein antigen–antibody complexes or other forms of ICs. This is followed by a second wave of IC production in the form of RF acting as antibody reactive with the initial ICs. Both of these processes are associated with complement consumption and production of inflammatory mediators. We present a model of an initiation phase of RA that might represent an example of repetitive formation of ICs and complement-mediated inflammation. Targeting therapy at this phase of RA to break the cycles of recurrent inflammation might be a novel approach to aid in further control of the disease.
Abstract 15501: Elevated Levels of Monocyte Activation Markers, Soluble CD14 and CD163, are Associated With Subclinical Atherosclerosis in the Multicenter AIDS Cohort Study (MACS)
Authors: Rebeccah A McKibben, Stephen Grinspoon, Xiuhong Li, Frank Palella, Lawrence A Kingsley, Mallory D Witt, Todd T Brown, Lisa P Jacobson, Matthew Budoff, Wendy S Post
Journal: Circulation (2013)

Background: We previously demonstrated higher prevalence and extent of non-calcified coronary plaque in HIV-infected men. Levels of pro-inflammatory monocytes may be elevated in HIV infection and associated with atherosclerosis. We tested the associations between soluble CD163 and CD14 with subclinical coronary atherosclerosis in HIV seropositive (SP) and seronegative (SN) men in the MACS. Methods: We measured soluble CD163 and CD14 and CAD risk factors and performed non-contrast CT scans to evaluate CAC in 521 HIV SP and 270 SN men, age 40-70. Coronary CT angiogram was performed on 391 HIV SP and 223 SN men to measure non-calcified plaque score (NCPS), total plaque score (TPS) and coronary stenosis. Logistic regression tested for associations between plaque presence (score > 0) and each biomarker. Linear regression tested for associations between extent of plaque among men with plaque present. Models were adjusted for age, race, and CAD risk factors. CD163 levels were log transformed. Tests for interacti...
Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).
Authors: S. A. Parikh, W. G. Wierda, X. Badoux, S. M. O'Brien, A. Ferrajoli, S. Faderl, J. A. Burger, S. Lerner, H. Kantarjian, M. J. Keating
Journal: Journal of Clinical Oncology (2010)

6519 Background: A phase III study showed that treatment with FCR was associated with significant improvement in progression-free survival (PFS) and overall survival (OS) compared to FC in previously untreated patients (pts) with CLL. This benefit was clearly demonstrated for pts with Binet stage A and B; but was less clear for pts with Binet C disease. We report a historic comparison of pts with Rai III/IV CLL treated with front-line FC versus FCR at our institution. Methods: FC consisted of F: 30 mg/m2 and C: 300 mg/m2 on D1-3 ± GM-CSF 275 mg/m2 daily, every 4 weeks for 6 courses. FCR consisted of F: 25 mg/m2 and C: 250 mg/m2 on D2-4; R: 375 mg/m2 on D1 (for the first course) and 500 mg/m2 for courses 2-6, every 4 weeks for 6 courses. Indications for treatment and response assessment were according to 1996 NCI-WG guidelines for both groups. Results: Of 93 pts treated with FC, 38 (41%) had Rai III/IV CLL; and of 300 pts treated with FCR, 102 (34%) had Rai III/IV CLL. Baseline characteristics, complete remission (CR), overall response rate (ORR), PFS and OS of Rai III/IV CLL pts are shown (Table). There was a higher incidence of grade 3/4 neutropenia and thrombocytopenia with FCR compared to FC; however there was no significant difference in infectious complications between the two treatments. Conclusions: In pts with previously untreated Rai III/IV CLL, FCR was associated with significantly improved response rates and survival compared to historic patients treated with FC. Characteristic FC (range) FCR (range) P value N 38 102 Median age, yrs 57 (41-92) 60 (39-86) 0.56 Median HGB (g/dL) 10.4 (7.7-14.8) 10.7 (6.1-16) 0.32 Median PLT (k/μ L) 97 (24-414) 95 (8-406) 0.98 Median WBC (k/μ L) 101 (2-278) 61 (2-619) 0.11 Median ALC (k/μ L) 92 (9-259) 51 (8-558) 0.05 Median β2M (mg/L) 4.4 (1.7-10.7) 4.5 (1.8-12.7) 0.67 Karyotype n=29 FC; n=85 FCR Diploid 22 (76%) 49 (58%) 0.08 11q del 0 4 (5%) 0.23 + 12 2 (7%) 7 (8%) 0.81 Complex 3 (10%) 16 (19%) 0.29 Other 2 (7%) 9 (11%) 0.56 CR, % 29 66 0.001 ORR, % 79 92 0.000 Median PFS (mos) 36 79 0.000 Median OS (mos) 55 120 0.004 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Biogen Idec, Genentech, Roche Roche Biogen Idec, Genentech, Genzyme
Re: Zhihua Lu, Guiting Lin, Amanda Reed-Maldonado, Chunxi Wang, Yung-Chin Lee, Tom F. Lue. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol 2017;71:223–33
Authors: Zi-Jun Zou, Jia-Yu Liang, Yi-Ping Lu
Journal: European Urology (2016)
Can the vulnerable elders survey-13 and/or the G8 adequately identify elderly head and neck cancer patients in need of a comprehensive geriatric assessment?
Authors: Philip Debruyne, Tom Boterberg, Hans Pottel, Laurence Goethals, Nele Van Den Noortgate, Frédéric Duprez, Wilfried De Neve, Sylvie Rottey, Kurt Geldhof, Koen Van Eygen, Khalil Kargar-Samani, Véronique Ghekiere, Frank Cornelis, Supriya Mohile, Lies Pottel
Journal: Journal of Clinical Oncology (2011)